期刊文献+

过氧化物酶体增殖物激活受体基因单核苷酸多态性与动脉僵硬度的关系

Association between peroxisome proliferator-activated receptor gene single nucleotide polymorphisms and arterial stiffness in adult Chinese population
原文传递
导出
摘要 目的研究过氧化物酶体增殖物激活受体(PPAR)基因单核苷酸多态性(SNP)与动脉僵硬度的关系。方法以流行病学调查方法了解心血管危险因素情况,用Complior系统测量颈股段脉搏波传导速度(efPWV)。用efPWV评价动脉僵硬度,将cfPWV〉12m/s作为动脉僵硬度增高标准,将研究对象分为动脉僵硬度正常组(844例)与增高组(530例)。用实时定量聚合酶链反应、TaqMan探针法获得1374例PPARet、PPARB、PPARγC1a基因的rs1053049、rs1800234和rs8192678等3个SNP位点基因型,分析传统心血管危险因素、基因型与动脉僵硬度的关系。结果动脉僵硬度增高组的平均年龄[(67.9±8.8)岁比(58.0±9.7)岁]、高血压[71.1%(377/530)比30.5%(257/844)]和糖尿病发生率[21.7%(115/530)比11.0%(93/844)]均高于动脉僵硬度正常组(P均〈0.01)。动脉僵硬度正常与增高组,rs8192678的CC基因型分别为272例(32.2%)和163例(30.8%),CT基因型分别为411例(48.7%)和276例(52.1%),TT基因型分别为161例(19.1%)和91例(17.2%);rs1053049的CC基因型分别为470例(55.7%)和272例(51.3%),CT基因型分别为310例(36.7%)和207例(39.1%),TT基因型分别为64例(7.6%)和51例(9.6%);rs1800234其CC基因型分别为746例(88.4%)和479例(90.4%),CT+TT基因型分别为98例(11.6%)和51例(9.6%)。两组间3个SNP位点分布差异均无统计学意义。结论年龄、高血压、糖尿病等心血管危险因素与动脉僵硬度相关,未发现PPAR、PPARγC1a基因的SNP位点与动脉僵硬度相关。 Objective To analyze the association between single nucleotide polymorphisms (SNPs) of peroxisomc proliferator-activated receptor(PPAR) and arterial stiffness in adult Chinese population ( 〉 50 years). Methods Cardiovascular risk factors from participants of Beijing epidemiological investigation were analyzed. Carotid-femoral pulse wave velocity (cfPWV) was measured by Complior system. The subjects were divided into normal arterial stiffness group (cfPWV 〈 12 m/s, n = 844 ) and increased arterial stiffness group (cfPWV 〉 12 m/s, n = 530). Three valid SNPs including rs1053049, rs1800234 and rs8192678 in the PPAR and PPARγCla gene were genotyped by TaqMan allelic discrimination assays. Results The age [(67.±8.8) years vs. (58.0±9.7) years], prevalence of hypertension[71.1% (377/530) vs. 30.5% (257/844)] and diabetes mellitus [21.7% (115/530) vs. 11.0% (93/844)] were all significantly higher in increased arterial stiffness group than in normal group (all P 〈 0. 05 ) . The frequencies of CC, CT and TT type of rs8192678 [ CC:32. 2% (272/844) vs. 30. 8% ( 163/530), CT: 48. 7% (411/844) vs. 52. 1% (276/530), TT: 19. 1% (161/844) vs. 17.2% (91/530) ], rs1053049 [CC: 55.7% (470/844) vs. 51.3% (272/530), CT: 36. 7% (310/844) vs. 39.1% (207/530), TY: 7.6% (64/844) vs. 9.6% (51/530) ] and rs1800234 [ CC : 88.4% (746/844) vs. 90.4% (479/530), CT +TT : 11.6% (98/844) vs. 9.6% ( 51/530) ] were similar between the two groups. There was also no association between haplotypes and the increased arterial stiffness in this cohort. Conclusions In this community-based population, we found that aging, hypertension and diabetes mellitus were associated but SNPs of PPAR and PPARγCla were not associated with arterial stiffness.
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2013年第4期288-292,共5页 Chinese Journal of Cardiology
关键词 动脉硬化 多态性 单核苷酸 过氧化物酶体增殖物激活受体 Arteriosclerosis Polymorphisms, single nucleotide Peroxisome proliferator- activated receptors
  • 相关文献

参考文献27

  • 1Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis.J Am Coli Cardiol, 2010, 55 :1318-1327.
  • 2李岩,马淑梅,杜敏,初巍巍,程小敏.培哚普利、氨氯地平、替米沙坦对血压及臂踝脉搏波传导速度的影响[J].中华心血管病杂志,2009,37(10):908-912. 被引量:13
  • 3Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur HeartJ ,2007 ,28: 1462-1536.
  • 4Yasmin , 0' Shaughnessy KM. Genetics of arterial structure and function: towards new biomarkers for aortic stiffness? Clin Sci (Lond),2008,114:661-677.
  • 5Lefebvre P, Chinetti G, FruchartJC, et al. Sorting out the roles of PP AR alpha in energy metaholism and vascular homeostasis.J Clin Invest ,2006 ,116 :571-580.
  • 6Fievet C, Staels B. Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease. CUIT Atheroscler Rep, 2009 ,11 : 281-288.
  • 7罗玉梅,万新红,姜德谦,旷文勇,郭洪波,陈朝霞,王合金,谢丽华,段雯.过氧化物酶增殖物激活受体-γ调节体外诱导培养的人巨噬细胞表达基质金属蛋白酶-9及其抑制物-1的作用及机制[J].中华心血管病杂志,2009,37(8):739-745. 被引量:5
  • 8Cresci S, W uJ, Province MA, et al. Peroxisome proliferator?activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diahetes trial. Circulation, 2011 ,124: 1426-1434.
  • 9Xu R, Ye P, Luo L, et al. Association between high-sensitivity cardiac troponin T and predicted cardiovascular risks in a community-based population. IntJ Cardiol, 2011,149 :253-256.
  • 101 Laurent S, CockcroftJ, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur HeartJ ,2006,27 :2588-2605.

二级参考文献34

  • 1刘晓楣,王朝晖,罗丰.过氧化酶体增殖物激活型受体γ对单核或巨噬细胞中抑制蛋白及基质金属蛋白酶-1表达的调控[J].临床心血管病杂志,2004,20(9):556-558. 被引量:5
  • 2杨智勇,于海杰,李晓东.急性冠脉综合征患者血清基质金属蛋白酶-9、C反应蛋白、白介素-6的变化及临床意义[J].中国老年学杂志,2007,27(3):259-260. 被引量:7
  • 3Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem, 2008,54:24-38.
  • 4Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med,2005,352:1685-1695.
  • 5Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation,2003, 108 : 1664-1672.
  • 6Inokubo Y, Hanada H, Ishizaka H, et al. Plasma levels of matrix metallopoteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J, 2001, 141:211-217.
  • 7Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPARgamma : differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP- 9 activity through PPAR gamma activation in mononuclear phagocytes in vitro. Am J Pathol,1998, 153 : 17-23.
  • 8Hanefeld M, Marx N, Pfutzner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coil Cardiol, 2007,49:290-297.
  • 9Dolezalova R, Haluzik MM, Bosanska L, et al. Effect of PPAR- gamma agonist treatment on markers of endothelial dysfunction in patients with type2 diabetes mellitus. Physiol Res, 2007,56:741- 748.
  • 10Pakala R, Dilcher C, Baffour R, et al. Peroxisome proliferator- activated receptor gamma ligand pioglitazone alters neointimal composition in a balloon-denuded and radiated hypercholesterolemic rabbit. J Cardiovasc Pharmacol, 2006,48 : 299 -305.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部